Du är här

2016-05-13

Bionor Pharma ASA: Notice of Extraordinary General Meeting 6 June 2016

BIONOR PHARMA ASA

STOCK EXCHANGE ANNOUNCEMENT

Notice of Extraordinary General Meeting 6 June 2016

(Oslo, Norway, 13 May 2016) An Extraordinary General Meeting of Bionor Pharma
ASA will be held on Monday 6 June 2016 at 15:00 hours at Kronprinsesse
Märthas plass 1, Oslo, Norway, at the meeting room on the 9thfloor.

At the Annual General Meeting on 22 April 2016, a number of the proposed
resolutions were not approved. The new Board has completed a renewed
evaluation of the proposals made, but not resolved at the Annual General
Meeting. Following the renewed evaluation, the Board has unanimously resolved
to call an Extraordinary General Meeting.

The notice of the Extraordinary General Meeting on 6 June 2016 is attached
hereto and includes detailed registration and proxy instructions.

All relevant documents and link to online registration of attendance and
advance voting can be found on www.bionorpharma.com.

Please note that to attend the Extraordinary General Meeting, attendants must
be registered shareholders five working days prior to the meeting - 30 May
2016.

This information is subject of the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.

Further information

Cecilie Grue, Director Legal Affairs, +47 99162486, cg@bionorpharma.com

Jørgen Fischer Ravn, VP Investor Relations&Communications, +45 20 30 39
03,jfr@bionorpharma.com

About Bionor

Bionor Pharma is a Norwegian biopharmaceutical company focused on advancing
its proprietary therapeutic vaccine Vacc-4x in combination with other
medicines toward a functional HIV cure. The company believes it has first
mover potential based on clinical results to date and early adoption of now
recognized clinical strategy. In December 2015, Bionor announced that the HIV
'Shock&Kill' trial REDUC with Vacc-4x and romidepsin successfully met its
primary endpoint by reducing latent HIV reservoir and further demonstrated
control of viral load. Bionor is currently planning BIOSKILL, a
proof-of-concept Phase II trial, which may lead to a major value inflection
point and partnering opportunities. Bionor currently retains full ownership
rights to Vacc-4x, i.e., the upside potential from partnering or licensing
remains with the company. Bionor is based in Oslo, Norway, and also has
offices in Copenhagen, Denmark and New York, USA. Bionor is listed on Oslo
Børs (OSE:BIONOR). More information about Bionor is available
atwww.bionorpharma.com.

Notice of EGM 6 June 2016
http://hugin.info/131219/R/2012575/745646.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Bionor Pharma ASA via Globenewswire

HUG#2012575

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.